129 related articles for article (PubMed ID: 37395154)
21. Metformin and Sulfonylurea Use and Risk of Incident Dementia.
Scherrer JF; Salas J; Floyd JS; Farr SA; Morley JE; Dublin S
Mayo Clin Proc; 2019 Aug; 94(8):1444-1456. PubMed ID: 31378227
[TBL] [Abstract][Full Text] [Related]
22. Metformin Use Is Associated With a Lower Risk of Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus: a Retrospective Cohort Analysis.
Tseng CH
J Am Heart Assoc; 2019 Nov; 8(21):e011640. PubMed ID: 31630591
[TBL] [Abstract][Full Text] [Related]
23. Metformin use is associated with a reduced risk of acute appendicitis in Taiwanese patients with type 2 diabetes mellitus.
Tseng CH
Sci Rep; 2021 Jun; 11(1):12400. PubMed ID: 34117321
[TBL] [Abstract][Full Text] [Related]
24. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
25. Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data model: A retrospective observational study.
Lee KA; Jin HY; Kim YJ; Kim SS; Cho EH; Park TS
Medicine (Baltimore); 2022 Feb; 101(8):e28823. PubMed ID: 35212277
[TBL] [Abstract][Full Text] [Related]
26. Metformin Use and Leukemia Risk in Patients With Type 2 Diabetes Mellitus.
Tseng CH
Front Endocrinol (Lausanne); 2020; 11():541090. PubMed ID: 33193076
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study.
Chang CH; Chang YC; Lin JW; Chen ST; Chuang LM; Lai MS
J Clin Endocrinol Metab; 2015 Mar; 100(3):1121-9. PubMed ID: 25555040
[TBL] [Abstract][Full Text] [Related]
28. Metformin Adherence Reduces the Risk of Dementia in Patients With Diabetes: A Population-based Cohort Study.
Chen PC; Hong CT; Chen WT; Chan L; Chien LN
Endocr Pract; 2023 Apr; 29(4):247-253. PubMed ID: 36657564
[TBL] [Abstract][Full Text] [Related]
29. Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus.
Newby D; Linden AB; Fernandes M; Molero Y; Winchester L; Sproviero W; Ghose U; Li QS; Launer LJ; Duijn CMV; Nevado-Holgado AJ
BMJ Open Diabetes Res Care; 2022 Sep; 10(5):. PubMed ID: 36109050
[TBL] [Abstract][Full Text] [Related]
30. Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study.
Lu CH; Yang CY; Li CY; Hsieh CY; Ou HT
Diabetologia; 2018 Mar; 61(3):562-573. PubMed ID: 29138876
[TBL] [Abstract][Full Text] [Related]
31. Dementia Diagnosis Is Associated with Changes in Antidiabetic Drug Prescription: An Open-Cohort Study of ∼130,000 Swedish Subjects over 14 Years.
Secnik J; Xu H; Schwertner E; Hammar N; Alvarsson M; Winblad B; Eriksdotter M; Garcia-Ptacek S; Religa D
J Alzheimers Dis; 2020; 76(4):1581-1594. PubMed ID: 32741836
[TBL] [Abstract][Full Text] [Related]
32. Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus.
Tseng CH
Aging (Albany NY); 2016 Aug; 8(8):1636-49. PubMed ID: 27587088
[TBL] [Abstract][Full Text] [Related]
33. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.
Douros A; Dell'Aniello S; Yu OHY; Filion KB; Azoulay L; Suissa S
BMJ; 2018 Jul; 362():k2693. PubMed ID: 30021781
[TBL] [Abstract][Full Text] [Related]
34. Metformin use and risk of cancer in patients with type 2 diabetes: a cohort study of primary care records using inverse probability weighting of marginal structural models.
Farmer RE; Ford D; Mathur R; Chaturvedi N; Kaplan R; Smeeth L; Bhaskaran K
Int J Epidemiol; 2019 Apr; 48(2):527-537. PubMed ID: 30753459
[TBL] [Abstract][Full Text] [Related]
35. Consequences of delaying treatment intensification in type 2 diabetes: evidence from a UK database.
Watson L; Das R; Farquhar R; Langerman H; Barnett AH
Curr Med Res Opin; 2016 Sep; 32(9):1465-75. PubMed ID: 26907851
[TBL] [Abstract][Full Text] [Related]
36. Metformin use is associated with a lower risk of rotator cuff disease in patients with Type 2 diabetes mellitus.
Chang R; Tu TY; Hung YM; Huang JY; Chou MC; Wei JC
Diabetes Metab; 2022 Sep; 48(5):101368. PubMed ID: 35760373
[TBL] [Abstract][Full Text] [Related]
37. Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia.
Charpignon ML; Vakulenko-Lagun B; Zheng B; Magdamo C; Su B; Evans K; Rodriguez S; Sokolov A; Boswell S; Sheu YH; Somai M; Middleton L; Hyman BT; Betensky RA; Finkelstein SN; Welsch RE; Tzoulaki I; Blacker D; Das S; Albers MW
Nat Commun; 2022 Dec; 13(1):7652. PubMed ID: 36496454
[TBL] [Abstract][Full Text] [Related]
38. The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment.
Pan SW; Yen YF; Kou YR; Chuang PH; Su VY; Feng JY; Chan YJ; Su WJ
Chest; 2018 Jun; 153(6):1347-1357. PubMed ID: 29253553
[TBL] [Abstract][Full Text] [Related]
39. Metformin and risk of developing nasopharyngeal cancer in patients with type 2 diabetes mellitus.
Tseng CH
Metabolism; 2018 Aug; 85():223-226. PubMed ID: 29729227
[TBL] [Abstract][Full Text] [Related]
40. The association of antidiabetic medications and Mini-Mental State Examination scores in patients with diabetes and dementia.
Secnik J; Xu H; Schwertner E; Hammar N; Alvarsson M; Winblad B; Eriksdotter M; Garcia-Ptacek S; Religa D
Alzheimers Res Ther; 2021 Dec; 13(1):197. PubMed ID: 34857046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
